» Articles » PMID: 24736226

Vaccine-induced Measles Virus-specific T Cells Do Not Prevent Infection or Disease but Facilitate Subsequent Clearance of Viral RNA

Overview
Journal mBio
Specialty Microbiology
Date 2014 Apr 17
PMID 24736226
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Infection with wild-type measles virus (MeV) induces lifelong protection from reinfection, and parenteral delivery of the live attenuated measles vaccine (LAV) also provides protection from measles. The level of neutralizing antibody is a good indicator of protection, but the independent roles of MeV-specific antibody and T cells have not been identified. In this study, macaques immunized with LAV through a nebulizer and a mouthpiece developed MeV-specific T-cell responses but not neutralizing antibodies. Upon challenge with wild-type MeV, these animals developed rashes and viremias similar to those in naive animals but cleared viral RNA from blood 25 to 40 days faster. The nebulizer-immunized animals also had more robust MeV-specific CD4(+) and CD8(+) T-cell responses than the naive animals after challenge, characterized by a higher number and better durability of gamma interferon (IFN-γ)-producing cells. Induction of MeV-specific circulating CD4(+) and CD8(+) T cells capable of producing multiple cytokines correlated with clearance of viral RNA in the nebulizer-immunized macaques. These studies demonstrated that MeV-specific T-cell immunity alone did not prevent measles, but T-cell priming enhanced the magnitude, durability, and polyfunctionality of MeV-specific T cells after challenge infection and correlated with more rapid clearance of MeV RNA. IMPORTANCE The components of vaccine-induced immunity necessary for protection from infection and disease have not been clearly identified for most vaccines. Vaccine development usually focuses on induction of antibody, but T-cell-based vaccines are also under development. The live attenuated measles vaccine (LAV) given subcutaneously induces both T cells and neutralizing antibody and provides solid protection from infection. LAV delivered to the upper respiratory tract through a nebulizer and mouthpiece induced a T-cell response but no neutralizing antibody. These T-cell-primed macaques demonstrated no protection from rash or viremia when challenged with wild-type MeV, but viral RNA was cleared more rapidly than in unimmunized animals. Thus, T-cell immunity did not protect from infection or acute disease but facilitated virus clearance during recovery. These studies demonstrate the importance and independent roles of T cells and antibody in protection and recovery from measles.

Citing Articles

Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity.

Emmelot M, Bodewes R, Maissan C, Vos M, de Swart R, van Els C NPJ Vaccines. 2025; 10(1):36.

PMID: 39979288 PMC: 11842548. DOI: 10.1038/s41541-025-01088-y.


Induction of tissue resident memory T cells by measles vaccine vector.

Vera-Peralta H, Ruffie C, Najburg V, Brione M, Combredet C, Frantz P Hum Vaccin Immunother. 2024; 20(1):2436241.

PMID: 39693193 PMC: 11657113. DOI: 10.1080/21645515.2024.2436241.


The contributions of T cell-mediated immunity to protection from vaccine-preventable diseases: A primer.

Shapiro J, Corrado M, Perry J, Watts T, Bolotin S Hum Vaccin Immunother. 2024; 20(1):2395679.

PMID: 39205626 PMC: 11364080. DOI: 10.1080/21645515.2024.2395679.


Immunogenicity of a peptide-based vaccine for measles: a pilot evaluation in a mouse model.

Quach H, Ratishvili T, Haralambieva I, Ovsyannikova I, Poland G, Kennedy R Sci Rep. 2024; 14(1):18776.

PMID: 39138335 PMC: 11322560. DOI: 10.1038/s41598-024-69825-2.


What's going on with measles?.

Moss W, Griffin D J Virol. 2024; 98(8):e0075824.

PMID: 39041786 PMC: 11334507. DOI: 10.1128/jvi.00758-24.


References
1.
Graves M, Griffin D, Johnson R, Hirsch R, De Soriano I, ROEDENBECK S . Development of antibody to measles virus polypeptides during complicated and uncomplicated measles virus infections. J Virol. 1984; 49(2):409-12. PMC: 255480. DOI: 10.1128/JVI.49.2.409-412.1984. View

2.
Hansen S, Ford J, Lewis M, Ventura A, Hughes C, Coyne-Johnson L . Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011; 473(7348):523-7. PMC: 3102768. DOI: 10.1038/nature10003. View

3.
Ryon J, Moss W, Monze M, Griffin D . Functional and phenotypic changes in circulating lymphocytes from hospitalized zambian children with measles. Clin Diagn Lab Immunol. 2002; 9(5):994-1003. PMC: 120077. DOI: 10.1128/cdli.9.5.994-1003.2002. View

4.
Seder R, Darrah P, Roederer M . T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008; 8(4):247-58. DOI: 10.1038/nri2274. View

5.
Hirsch R, Griffin D, Johnson R, Cooper S, Lindo de Soriano I, ROEDENBECK S . Cellular immune responses during complicated and uncomplicated measles virus infections of man. Clin Immunol Immunopathol. 1984; 31(1):1-12. DOI: 10.1016/0090-1229(84)90184-3. View